Matches in Nanopublications for { ?s ?p "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP960930.RAXU_FW9u_eO7pATgiKKDzXxX3zeXEpGFXjViMn8onWYg130_assertion description "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP960930.RAXU_FW9u_eO7pATgiKKDzXxX3zeXEpGFXjViMn8onWYg130_provenance.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion description "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.